Diego A. Díaz García, Medical Oncologist /CEO/Founder at CánCare – High Specialty in Oncology, shared on X:
“cfDNA fragmentomics is redefining cancer detection. Beyond mutations and methylation, genome-wide fragmentation patterns offer new biomarkers.
- Reflects genomic and epigenomic states
- Enhances early detection via AI-driven analysis”
